Key Highlights

● Panbela moved from Nasdaq to the OTCQB on April 17, 2024, after missing the minimum stockholders' Equity requirement.

● Ivospemin is in the Phase 3 ASPIRE trial for metastatic pancreatic cancer, with interim analysis expected in early 2025.

● Third-quarter 2024 net loss was $7.2 million, and cash at September 30, 2024 was only $142 thousand.

● Current liabilities of $20.1 million far exceeded current Assets of $5.2 million, and Nant Capital committed $12.0 million of financing.

Panbela Therapeutics (OTC:PBLA) is a clinical-stage biopharmaceutical company, and its common stock has been quoted over the counter since April 2024. The shares are high risk because the company has little cash, large short-term obligations and a lead programme that is still in a pivotal trial.

Panbela moved from the Nasdaq Capital Market to the OTCQB market after Nasdaq determined on March 5, 2024 that it did not meet the minimum stockholders' equity requirement. The company announced on April 16, 2024 that Quotation on the OTCQB was approved, effective April 17, 2024. Third-party sites now describe the quote as OTC Markets generally, so the current tier is unconfirmed.

Pipeline and business

The company develops treatments for urgent unmet medical needs. Its lead candidate, ivospemin, also known as SBP-101, is a polyamine analogue studied in metastatic pancreatic cancer. It is being tested in the Phase 3 ASPIRE trial. A second asset, Flynpovi, combines eflornithine and sulindac and is aimed at familial adenomatous polyposis and colorectal cancer prevention, while a Phase 1 study of a related compound with Keytruda in STK11-mutant non-small cell lung cancer enrolled its first patient in September 2024.

An independent data safety monitoring board reviewed ASPIRE for a third time in June 2024 and recommended that it continue without modification. Management said interim analysis was expected in the first quarter of 2025, later than first planned because of a lower-than-expected event rate, which it suggested might indicate better survival. That interpretation is the company's, not a proven result.

Latest verified financial results

The most recent results are for the third quarter of 2024, published on November 14, 2024. Panbela reported a net loss of $7.2 million for the quarter, with Research and Development expense of $6.0 million and general and administrative expense of $1.1 million. Cash at September 30, 2024 was only $142 thousand.

Current liabilities of $20.1 million far exceeded current assets of $5.2 million. Notes payable including accrued interest were $6.9 million. Over nine months the company raised $8.1 million net from a public offering and $2.2 million in bridge notes, yet cash still fell by $2.4 million after roughly $12.5 million of operating cash use.

The company also announced a $12.0 million financing commitment from Nant Capital in that release. An August 15, 2024 release had already noted a $1.5 million Loan from partner US WorldMeds in July and a stockholders' Deficit of $10.6 million at June 30, 2024.

Material risks

The Balance Sheet is the central concern. Liabilities exceeding assets by this margin, with cash measured in thousands, leave the company reliant on lenders and further equity sales, which can dilute existing holders. Clinical risk is equally important: ASPIRE could Fail to show a survival benefit, and a trial setback would remove the main basis for the company's value.

Venue risk adds to this. Moving off Nasdaq reduced reporting scrutiny for some investors, narrowed the pool of institutions able to hold the shares and typically widens bid-ask spreads. Price, Market Capitalisation and share count data conflict with one another.

ASPIRE Interim Analysis and Funding Documents Are the Next Markers for Panbela

The latest company announcement or filing that can be verified is dated November 2024. Open items are the ASPIRE interim analysis outcome, the latest annual and quarterly reports on the SEC's EDGAR system, evidence of how the Nant Capital commitment was drawn, and confirmation of the current OTC tier. Without those documents, the position beyond late 2024 remains unconfirmed.